Trial Profile
A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms APOLLO
- 07 Feb 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Feb 2022).
- 15 Jun 2023 Results comparing the effectiveness of talquetamab in MonumenTAL-1 (NCT03399799/NCT04636552), vs physicians choice (PC) therapy CASTOR , POLLUX , EQUULEUS , APOLLO, presented at the 28th Congress of the European Haematology Association
- 01 May 2023 results of Comparative Efficacy of Teclistamab from NCT04557098 Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials